<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814736</url>
  </required_header>
  <id_info>
    <org_study_id>A3711051</org_study_id>
    <nct_id>NCT00814736</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate The Safety And Toleration Of Single Dose Sildenafil In Subjects Receiving Chronic UK-369,003.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and overall tolerability of co-administration two PDE5 inhibitors
      UK369,003 and sildenafil
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toleration assessed by non-leading questioning, incidence of adverse events and laboratory testing.</measure>
    <time_frame>hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of postural hypotension.</measure>
    <time_frame>hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing and supine pulse rate (PR) at each postdose time.</measure>
    <time_frame>hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing systolic and diastolic blood pressure (BP) and supine systolic and diastolic BP at each postdose time.</measure>
    <time_frame>hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Urinary Bladder, Overactive</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>UK369,003 + Placebo or sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UK369,003</intervention_name>
    <description>oral tablet, once a day</description>
    <arm_group_label>UK369,003 + Placebo or sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>single oral dose on day 14 or day 17</description>
    <arm_group_label>UK369,003 + Placebo or sildenafil</arm_group_label>
    <other_name>viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil matching placebo</intervention_name>
    <description>single oral dose on day 14 or day 17</description>
    <arm_group_label>UK369,003 + Placebo or sildenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject (or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.

          -  Healthy male subjects between the ages of 40 and 55 years, inclusive

          -  Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg
             (110 lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant haematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Loss of vision in one eye due to non-arteritic ischemic optic neuropathy (NAION)
             regardless of whether or not this event was temporally associated with the use of a
             PDE5 inhibitor.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3711051&amp;StudyName=A%20randomized%2C%20double-blinded%2C%20placebo-controlled%2C%20two-way%20crossover%20study%20to%20investigate%20the%20safety%20and%20toleration%20of%20single%20dose%20Silden</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>December 22, 2008</last_update_submitted>
  <last_update_submitted_qc>December 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

